Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | PRIME-HCC: ipilimumab and nivolumab in liver cancer

David Pinato • 16 Apr 2021
Gastrointestinal Cancer Liver Cancer Antibodies Ipilimumab Nivolumab

David Pinato, MD, MRes, PhD, Imperial College London, London, UK, shares an update on the Phase Ib PRIME-HCC trial (NCT03682276) of neoadjuvant ipilimumab and nivolumab before liver resection in patients with hepatocellular cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Disclosures

David Pinato, MD, MRes, PhD, has received lecture fees from ViiV Healthcare and Bayer Healthcare; has received travel expenses from BMS and Bayer Healthcare; has received consulting fees from Mina Therapeutics, EISAI, Roche and Astra Zeneca; and has received research funding (to the institution) from MSD and BMS.

More from David Pinato

3:22
COVID-19 and cancer outcomes in the UK
David Pinato • 19 Apr 2021
2:03
Antibiotics impact outcomes with pembrolizumab in NSCLC patients
David Pinato • 16 Apr 2021
1:23
PD-1/VEGFR blockade for liver cancer
David Pinato • 16 Apr 2021

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals